FDA clears at‑home HPV kit
The FDA has cleared Waters' Onclarity HPV Self‑Collection Kit for at‑home use together with the BD Onclarity HPV Assay that supports extended genotyping, opening an at‑home molecular screening pathway for cervical cancer. Waters and reporting note the clearance pairs self‑collection with automated lab workflows and extended genotype results that will change how labs handle accessioning, reflex triage and reportable risk categories. (reuters.com)
Most cervical cancer starts with a virus that usually causes no symptoms for years, which is why screening works best before anyone feels sick. On April 8, 2026, the Food and Drug Administration cleared a new option that lets a patient collect that screening sample at home instead of during a clinic pelvic exam. (fda.gov) (reuters.com) The virus is called human papillomavirus, and the dangerous version is the “high-risk” kind that can push cervical cells toward cancer over time. The cleared setup pairs the Waters Onclarity self-collection kit with the BD Onclarity laboratory test, which looks for deoxyribonucleic acid from 14 high-risk human papillomavirus types. (cancer.gov) (fda.gov) Think of the sample as a swab that gathers clues, and the lab test as the barcode scanner that sorts those clues into specific virus types. BD says its test can report six high-risk types individually — including human papillomavirus 16 and human papillomavirus 18 — and group the rest into three pooled buckets. (bd.com) (pharmacytimes.com) That extra sorting is called genotyping, and it changes what happens after a positive result because some virus types carry more risk than others. BD says the assay’s “extended genotyping” can help labs and clinicians make more tailored follow-up decisions instead of treating every positive test the same way. (bd.com) The United States already moved partway in this direction in May 2024, when the Food and Drug Administration allowed BD’s Onclarity test and Roche’s cobas test to be used with self-collected vaginal samples in a health care setting. The missing piece then was the location: patients could collect the sample themselves, but they still had to do it in a clinic, pharmacy, or mobile site. (cancer.gov) This new clearance moves the collection step into the home while keeping the actual analysis in a clinical laboratory. Waters says the test is designed to run through the automated BD COR system, which means labs can process mailed-in samples with the same kind of barcode-driven workflow they already use for other molecular tests. (ir.waters.com) (grafa.com) That lab piece is why this is not the same as an instant home pregnancy test or a rapid coronavirus test. The patient collects the sample at home, but a certified lab still runs a polymerase chain reaction test — a method that amplifies tiny bits of viral genetic material until the machine can detect them. (fda.gov) (pharmacytimes.com) The companies are aiming this at a stubborn gap in care: Waters says about 60% of cervical cancer cases occur in people who are unscreened or under-screened. The American Cancer Society says barriers include discomfort with pelvic exams, trouble getting appointments, transportation, child care, and time off work. (ir.waters.com) (cancer.org) Coverage and access will decide how big this becomes. Contemporary OB/GYN, citing the company announcement, reported that the kit will be prescription-only and covered by major insurers, including Medicare and Medicaid, while Waters said it is building partnerships to expand nationwide availability. (contemporaryobgyn.net) (ir.waters.com) The practical change for labs is that a mailed-in swab can now enter the same automated system that produces risk-tiered human papillomavirus results, which affects how samples are logged, which follow-up tests are triggered, and how results are reported back to clinicians. That turns cervical screening into something closer to a mail-order molecular lab workflow than a one-room exam. (reuters.com) (bd.com)
